SCHEMBL6399279

SCHEMBL6399279

NC(=O)c1cnn(-c2ccccc2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.56
ALDH1A1 P00352 2/20 0.56
HPGD P15428 2/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
HSD17B10 Q99714 1/20 0.56
P2RX7 Q99572 2/20 0.50
ADORA2A P29274 2/20 0.50
LMNA P02545 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
PKM P14618 1/20 0.50
ADORA2B P29275 1/20 0.50
ADORA1 P30542 1/20 0.50
KAT2B Q92831 1/20 0.50
HDAC1 Q13547 2/20 0.49
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
PARP1 P09874 1/20 0.46
RIPK2 O43353 1/20 0.46
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1752087 0.85 P2RX7 (0.53) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL23367502 0.83 ADAMTS7 (0.44) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL6311461 0.82 SLC9A1 (0.51) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL28090836 0.81 HDAC1 (0.51) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL6311452 0.80 HDAC1 (0.51) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL6464483 0.78 HDAC1 (0.55) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL13543694 0.78 P2RX7 (0.46) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL32674134 0.78 MAPT (0.59) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL14736048 0.75 P2RX7 (0.63) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL693372 0.75 CA5A (0.41) KDM4EALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-4058446-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed
US-20050182093-A1 Novel compounds GLAXOSMITHKLINE S.P.A. 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182093-A1 Novel compounds SLC10A1, AVPR2, REN KDM4E 3699/4885ALDH1A1 1675/4885HPGD 1933/4885
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAMTS1 KDM4E 2923/4885ALDH1A1 2009/4885HPGD 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.